mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma. (Q54345071)

28 May 2018

title

mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma. (English)

1 reference

28 May 2018

fibrolamellar hepatocellular carcinoma

main subject

0 references

Jeannette J Yu

0 references

Kimberly J Riehle

1 reference

28 May 2018

Matthew M Yeh

1 reference

28 May 2018

Heidi L Kenerson

1 reference

28 May 2018

William P Harris

1 reference

28 May 2018

James O Park

1 reference

28 May 2018

Raymond S Yeung

1 reference

28 May 2018

publication date

13 June 2014

1 reference

28 May 2018

published in

Modern Pathology

1 reference

28 May 2018

volume

1 reference

28 May 2018

issue

1 reference

28 May 2018

page(s)

103-110

1 reference

28 May 2018

Fibrolamellar carcinoma: 2012 update

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2014.78

Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2014.78

A unifying model for mTORC1-mediated regulation of mRNA translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2014.78

Pivotal role of mTOR signaling in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2014.78

Akt and mTORC1 have different roles during liver tumorigenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2014.78

Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2014.78

Fibroblast growth factor signalling: from development to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2014.78

Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2014.78

Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2014.78

EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2014.78

Hepatocellular carcinoma: recent trends in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2014.78

Outcome of patients with fibrolamellar hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2014.78

Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma--results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2014.78

Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2014.78

Long-term survival of fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: a US population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2014.78

Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2014.78

Fibrolamellar carcinomas are positive for CD68

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2014.78

Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2014.78

Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium

21 January 2018

1 reference

12 December 2020

Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation

1 reference

12 December 2020

Fibrolamellar hepatocellular carcinoma: an immunohistochemical comparison with conventional hepatocellular carcinoma

1 reference

12 December 2020

Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer

1 reference

12 December 2020

Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature.

1 reference

12 December 2020

Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways

1 reference

12 December 2020

Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism

1 reference

12 December 2020

Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors

1 reference

12 December 2020

10.1038/MODPATHOL.2014.78

Identifiers

DOI

1 reference

28 May 2018

Dimensions Publication ID

1032126699

0 references

1 reference

28 May 2018